ARTICLE | Company News
FDA reviewers say data are lacking on TIRF drug use
August 10, 2018 6:32 PM UTC
FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3.
Participants gave "important feedback" that insufficient data exists to identify how TIRF drugs are used and track adverse events, FDA Commissioner Scott Gottlieb said in a series of tweets on Aug. 3...